ViaCyte, Inc., a San Diego, California–based leader in the field of regenerative medicine, is developing a transformative cell replacement therapy that is designed to free individuals with diabetes from long-term dependence on insulin. The company’s pioneering product, VC-0, combines the differentiation of stem cells into pancreatic beta cell precursors (PEC-0) with subcutaneous drug delivery via implantation in a retrievable and immune-protective encapsuled medical device (Encaptra). Following implantation, the precursor cells mature into endocrine cells that secrete insulin and other hormones in a regulated manner to control blood glucose levels and eliminate the need for injected insulin. ViaCyte receives funding for its stem cell research from the California Institute for Regenerative Medicine (CIRM) and the Juvenile Diabetes Research Foundation (JDRF).


ViaCyte’s research is focused on human ...

  • Loading...
locked icon

Sign in to access this content

Get a 30 day FREE TRIAL

  • Watch videos from a variety of sources bringing classroom topics to life
  • Read modern, diverse business cases
  • Explore hundreds of books and reference titles